...
首页> 外文期刊>Future medicinal chemistry >CDK5 in oncology: recent advances and future prospects
【24h】

CDK5 in oncology: recent advances and future prospects

机译:CDK5在肿瘤学中:最近的进展和未来的前景

获取原文
获取原文并翻译 | 示例
           

摘要

Selective abrogation of cyclin-dependent kinases (CDK) activity is a highly promising strategy in cancer treatment. The atypical CDK, CDK5 has long been known for its role in neurodegenerative diseases, and is becoming an attractive drug target for cancer therapy. Myriads of recent studies have uncovered that aberrant expression of CDK5 contributes to the oncogenic initiation and progression of multiple solid and hematological malignancies. CDK5 is also implicated in the regulation of cancer stem cell biology. In this review, we present the current state of knowledge of CDK5 as a druggable target for cancer treatment. We also provide a detailed outlook of designing selective and potent inhibitors of this enzyme.
机译:选择性废除细胞周期蛋白依赖性激酶(CDK)活性是癌症治疗中具有高度有前途的策略。 非典型的CDK,CDK5长期以来一直以其神经变性疾病的作用而闻名,并且正在成为癌症治疗的有吸引力的药物目标。 最近的研究中的多年来已经发现,CDK5的异常表达有助于致癌发育和多种固体和血液恶性恶性肿瘤的进展。 CDK5也涉及癌症干细胞生物学的调节。 在本综述中,我们将CDK5的当前知识状态作为癌症治疗的可耐药靶标。 我们还提供了设计这种酶的选择性和有效抑制剂的详细观察。

著录项

  • 来源
    《Future medicinal chemistry》 |2017年第16期|共24页
  • 作者单位

    Univ South Australia Ctr Drug Discovery &

    Dev Sansom Inst Hlth Res Sch Pharm &

    Med Sci Adelaide;

    Univ South Australia Ctr Drug Discovery &

    Dev Sansom Inst Hlth Res Sch Pharm &

    Med Sci Adelaide;

    Univ South Australia Ctr Drug Discovery &

    Dev Sansom Inst Hlth Res Sch Pharm &

    Med Sci Adelaide;

    Univ South Australia Ctr Drug Discovery &

    Dev Sansom Inst Hlth Res Sch Pharm &

    Med Sci Adelaide;

    Univ South Australia Ctr Drug Discovery &

    Dev Sansom Inst Hlth Res Sch Pharm &

    Med Sci Adelaide;

    Univ South Australia Ctr Drug Discovery &

    Dev Sansom Inst Hlth Res Sch Pharm &

    Med Sci Adelaide;

    Univ South Australia Ctr Drug Discovery &

    Dev Sansom Inst Hlth Res Sch Pharm &

    Med Sci Adelaide;

    Univ South Australia Ctr Drug Discovery &

    Dev Sansom Inst Hlth Res Sch Pharm &

    Med Sci Adelaide;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

    cancer; cancer hallmarks; CDK; CDK5 inhibitors; p25; p35; targeted cancer therapy;

    机译:癌症;癌症标志;CDK;CDK5抑制剂;P25;P35;靶向癌症治疗;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号